Compare PAR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | DYN |
|---|---|---|
| Founded | 1968 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.9B |
| IPO Year | N/A | 2020 |
| Metric | PAR | DYN |
|---|---|---|
| Price | $37.06 | $19.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $64.00 | $40.25 |
| AVG Volume (30 Days) | 607.0K | ★ 3.3M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $440,451,000.00 | N/A |
| Revenue This Year | $30.40 | N/A |
| Revenue Next Year | $12.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.88 | N/A |
| 52 Week Low | $31.65 | $6.36 |
| 52 Week High | $81.51 | $27.59 |
| Indicator | PAR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 47.95 |
| Support Level | $33.29 | $19.20 |
| Resistance Level | $38.15 | $20.80 |
| Average True Range (ATR) | 1.40 | 1.49 |
| MACD | 0.49 | -0.29 |
| Stochastic Oscillator | 81.49 | 20.70 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.